Rakesh Malhotra is a Nephrology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 92103
Telephone
800-926-8273Registry record last updated 24 Sept 2019.
Clinical trials
- The "Step4Life" Randomized Control Trial in Hemodialysis
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20254 payments
- CALLIDITAS THERAPEUTICS US INC.Program year20242 payments
- Travere Therapeutics, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.4%Loop diuretic14.1%Bumetanide57%Furosemide44%Part D≥16 patientsCalcium channel blocker9%Nifedipine Er50%Amlodipine Besylate50%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
18.3%SGLT2 inhibitor15%Jardiance100%Part D≥20 patientsCorticosteroid3.3%Prednisone100%Part D<11 patientsOther
14.5%Phosphate Binder7.5%Sevelamer Carbonate73%Sevelamer Hcl27%Part D<11 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia7%Lokelma100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- StepNet-Adapt: A SMART Mobile Health Intervention to Promote Physical Activity in Hemodialysis Patients
University of California, San Diego
FY2026$796,998R01DK147813 - Non Invasive Assessment of Microcirculation Function and Kidney Disease
University of California, San Diego
FY2026$193,881K23DK132680 - Non Invasive Assessment of Microcirculation Function and Kidney Disease
University of California, San Diego
FY2025$194,037K23DK132680
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”